Get Support

Learn Mode

DHR - Danaher Corp

222

$190.79

$1.19 (0.628%)

At market close

$189.98

-$0.81 (-0.423%)

Pre Market 4/2/26, 11:56 AM

3.66/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

DHR

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$134.92B

Industry

Life Sciences Tools & Services

EPS (TTM)

$5.08

P/E (TTM)

37.33

Div & Yield

$1.60 (0.84%)

FCF Payout Ratio

21.51%

P/S (TTM)

5.49

P/B

2.57

Diluted Shares

710.70M

Ex-Dividend

2026-03-27

Next Earnings

04-21

Forward P/E

22.06

Payout Ratio

31.31%

P/FCF (TTM)

25.65

FCF Yield

3.90%

Earnings Yield

2.68%

52 Week Range

Score Card

Explore Scores Tab

3.66

Good

Danaher Corp has grown revenue at 2.9% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 21.41%, which suggests the company is very profitable.

Valuation Model

Key Score

3.00

Average

Management

2.00

Bad

Growth

1.00

Very Bad

Profitability

2.00

Bad

Fin. Health

1.00

Very Bad

Dividends

4.00

Good

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 17:39:08

Form ARS

Unknown Form Type

Filed on 2026-03-25 08:20:46

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-25 08:12:07

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-25 08:09:46

Form 25-NSE

Unknown Form Type

Filed on 2026-03-23 07:40:56

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:52:26

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:52:22

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:52:17

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:52:11

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:52:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:52:02

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 19:51:57

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$325.50

70.6%

Avg:

$268.58

40.8%

Low:

$222.20

16.5%

(% change is relative to the current stock price: $190.79)

Analyst Recommendations

Go to Analyst Tab

4.23

Very Good

37%

Strong Buy (11)

50%

Buy (15)

13%

Hold (4)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.danaher.com/
Address
2200 Pennsylvania Ave NW Ste 800W, WASHINGTON WASHINGTON DC, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=313616

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 58,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

IPO Date

1969-12-10

Industry

Life Sciences Tools & Services

Total Employees

58,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Life Sciences Tools & Services

GICS Sub

Life Sciences Tools & Services

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences